Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C

Status: Recruiting
Phase: Phase 4
Diagnosis: Gastrointestinal Malignancies
NCT ID: NCT01849588 (View complete trial on
DFCI Protocol ID: 12-213


This research study is a Phase IV clinical trial. Phase IV trials are used to further test and monitor the safety of a drug approved by the FDA and to see if the drug has any other indications that can be used to treat different diseases. Sorafenib is a new drug, which is approved under the brand name Nexavar for the treatment of liver cancer. It is also currently being tested in various other cancers. Sorafenib works by slowing down and/or stopping the development of new cancer cells and new blood vessels. By slowing down and/or stopping the growth of new blood vessels around a tumor, it is believed that sorafenib prevents or slows down the growth of tumors. The researchers of this study would like to study the effects of sorafenib on hepatitis C by drawing additional research blood samples from people infected with hepatitis C who are receiving sorafenib treatment for liver cancer. These tests will measure certain proteins in the blood (HCV-RNA) which may indicate if sorafenib has any effect on the hepatitis C virus.


Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital

Overall PI:
Thomas Abrams, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Andrew Zhu, MD, PhD, Massachusetts General Hospital

Dana-Farber Cancer Institute: Gastrointestinal Research Line, 617-632-5960
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Histologically and/or radiologically confirmed advanced HCC - Detectable HCV RNA with anti-HCV-positivity - Life expectancy of at least 3 months - Willing to use adequate contraception Exclusion Criteria: - Pregnant or breastfeeding - Undetectable HCV RNA - Uncontrolled hypertension - Active or clinically significant cardiac disease - Thrombolic, embolic, venous or arterial events within 6 months of informed consent - Pulmonary hemorrhage/bleeding event (NCI-CTCAE grade 2 or higher) within 4 weeks before study entry - Previously untreated or concurrent cancer except cervical cancer in situ, treated basal cell carcinoma or superficial bladder tumor - Presence of non-healing wound, ulcer or bone fracture - History of organ allograft - Known or suspected allergy or hypersensitivity to any of the study drugs - Any malabsorption condition - Inability to comply with the protocol and/or not willing or not available for follow up - Major surgery within 30 days prior to start of study drug
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms